Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial

2017 ESMO Congress
Tweet this page

Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).

Advertisement

Advertisement



Advertisement